Working Together Toward a TB-Free Ukraine

Johnson & Johnson is collaborating with the Government of Ukraine and other partners to comprehensively address the challenge of multidrug-resistant tuberculosis in Ukraine

THE CHALLENGE

Ukraine is one of the 30 countries with the highest multidrug-resistant TB (MDR-TB) burdens and second in Europe in TB mortality rate. According to the Ministry of Health, there are about 35,000 Ukrainians registered with TB, 8,000 of whom are MDR-TB patients. There is also a high proportion of people with TB—approximately one in five—co-infected with HIV.

To make TB history in Ukraine and around the world, it will be essential to accelerate the development and delivery of new innovations and creative solutions to help reach more patients.

ACTION TO END TB IN UKRAINE

The government of Ukrainian is committed to making progress towards achieving the goals of the Tuberculosis Action Plan for the End TB Strategy. In 2018, Ukraine implemented a new approach to TB control aimed at improving detection, treatment and financing of tuberculosis health-care services. Moreover, Ukraine adopted WHO-recommended guidelines to improve early detection and treatment.

Johnson & Johnson collaborated with key stakeholders—including the Ministry of Health, local patient advocacy groups and international partners—to broaden Ukrainian patients’ access to innovative therapy to improve their lives. Since 2017, patients in Ukraine have had access to our new targeted MDR-TB medicine, the first with a novel mechanism of action to be approved in more than 40 years. As part of the donation program launched by Johnson & Johnson & USAID, around 9,000 courses were delivered to Ukraine in 2018-2019.

Additionally, Johnson & Johnson has supported efforts to strengthen healthcare delivery systems by training health workers, improving diagnostic capacity, and supporting efforts to raise awareness and reduce stigma around TB at the community level. Beyond this, the enterprise is accelerating TB research and development (R&D) to discover innovative next-generation treatments and other tools that will be needed to reach the global goal of ending TB.

These efforts are part of a comprehensive 10-year TB initiative launched by Johnson & Johnson in September 2018. With a focus on treatment access, patient finding and R&D, Johnson & Johnson aims to help save 1.8 million lives and prevent 12 million infections globally over the next decade.

GLOBAL JOHNSON & JOHNSON TB PROGRAM AT A GLANCE

- First novel TB medicine in more than 40 years; approved in 67 countries
- Over 373K courses of treatment delivered for MDR-TB patients in 145 countries, including the 30 highest-burden countries (as of March 2021)
- Donating 105K courses of treatment to eligible countries through a four-year donation program with USAID and JSC Pharmstandard, implemented through the Stop TB Partnership’s Global Drug Facility

Last updated: March 2021

1. Tuberculosis surveillance and monitoring in Europe 2019 (2017 data)
COLLABORATING AT EVERY LEVEL

J&J is working with the Government of Ukraine and other partners to take a holistic approach to ending TB by accelerating affordable access to treatment, supporting health systems strengthening efforts, raising awareness and reducing stigma around TB among the general public, as well as driving cutting-edge research and development.

ACCESS
Delivering around 9,000 courses of our MDR-TB treatment to Ukraine between 2018-2019, in partnership with USAID

APPROPRIATE USE
Growing and consolidating private-public efforts for TB elimination by signing an MOU with the Center of Public Health under the Ministry of Health of Ukraine in May 2019

MEDICAL EDUCATION
Supporting the training of more than 2,000 healthcare professionals to date in MDR-TB clinical management

DETECTION & TESTING
Improving case finding and strengthening health systems to reach the thousands of people with undiagnosed TB and MDR-TB and connect them to care by increasing diagnostic capacity, training health workers and raising community awareness

DISCOVERY
Accelerating TB research and development (R&D) to discover innovative, next-generation treatments that will be needed to reach the global goal of ending TB

AREAS OF COOPERATION
Collaborating through conferences, seminars, training, and research activities and exchanging scientific and medical information

ABOUT J&J GLOBAL PUBLIC HEALTH
Through a dedicated global public health (GPH) organization that combines R&D, global access strategies and programs, and local operations, Johnson & Johnson is putting the world’s most vulnerable and underserved at the heart of everything we do — measuring our success in lives improved. As a team of innovators, we are committed to pioneering and sustainably delivering meaningful and transformation products. Upholding the rich heritage of Johnson & Johnson, we are taking on the toughest challenges, and, ultimately, we hope to do our part to close the gap of inequity and pave the way to a healthier future for the world’s most vulnerable and underserved populations.